Controlling and Lowering Blood Pressure With The MOBIUSHD™ (CALM-FIM_US)

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2015 by Vascular Dynamics, Inc.
Information provided by (Responsible Party):
Vascular Dynamics, Inc. Identifier:
First received: April 9, 2013
Last updated: May 26, 2015
Last verified: May 2015

To evaluate the safety and performance of the MobiusHD system in subjects with resistant hypertension.

Condition Intervention Phase
Device: MobiusHD™
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHD™ - A Prospective Multicenter Safety Study

Resource links provided by NLM:

Further study details as provided by Vascular Dynamics, Inc.:

Primary Outcome Measures:
  • Safety [ Time Frame: 6 month ] [ Designated as safety issue: Yes ]
    Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six (6) months of follow-up.

Secondary Outcome Measures:
  • PERFORMANCE [ Time Frame: 6 Months ] [ Designated as safety issue: No ]
    Decrease in office cuff blood pressure (BP).

Estimated Enrollment: 10
Study Start Date: May 2013
Estimated Study Completion Date: June 2018
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: MobiusHD™
Device: MobiusHD™
Implant that is placed in the carotid sinus to control hypertension.

Detailed Description:

This is an open-label, multicenter, first-in-man clinical trial to be conducted inside the United States. Eligible subjects with stage 2 resistant systemic arterial hypertension currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to study participation will be assigned to treatment with the MobiusHD system.

Potential study participants will be consented and then screened at two (2) baseline visits beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo placement of the MobiusHD under angiographic visualization, and will then be followed for 36 months.


Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following at least one (1) month of maximally tolerated therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic. Any combination medications will be counted per the active ingredient. (For example, Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)

Exclusion Criteria:

  • Known or clinically suspected baroreflex failure or autonomic neuropathy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01831895

Contact: Sujith J Shetty, MBBS 650-963-9370

United States, Alabama
Cardiology, P.C. Recruiting
Birmingham, Alabama, United States, 35211
Contact: Wesley Wade, RN, BSN    205-780-4330 ext 5280   
Principal Investigator: Farrell Mendelsohn, M.D.         
United States, Georgia
Emory University Recruiting
Atlanta, Georgia, United States, 30308
Contact: Theresa Sanders, MN, RN    404-686-3872   
Principal Investigator: Chandan Devireddy, MD         
United States, Iowa
Iowa Heart Center Recruiting
Des Moines, Iowa, United States, 50309
Contact: Tanya Watters, RN    515-235-5089   
Contact: Teresa Coulson, RN, CCRC    515-633-3840   
Principal Investigator: Magdhi Ghali, MD         
United States, Michigan
Michigan Heart Recruiting
Ypsilanti, Michigan, United States, 48197
Contact: Autumn Howe, RN, BSN    734-712-8387   
Principal Investigator: Herbert Aronow, M.D., MPH         
United States, New York
University of Rochester Recruiting
Rochester, New York, United States, 14627
Contact: Robin Stuart Buttles, CCRC, MSACN    585-341-7764   
Principal Investigator: Craig Narins, M.D.         
United States, Tennessee
Turkey Creek Medical Center Recruiting
Knoxville, Tennessee, United States, 37934
Contact: Beth Polk, RN, CCRC    865-218-7535   
Contact: Connie Bales, RN, CCRC    865-218-7540   
Principal Investigator: Malcolm Foster, MD         
United States, Wisconsin
Medical College of Wisconsin - Froedtert Hospital Recruiting
Milwaukee, Wisconsin, United States, 53226
Contact: Lavinia Padmore    414-805-5287   
Principal Investigator: Osama O Zaidat, MD, MS         
Sponsors and Collaborators
Vascular Dynamics, Inc.
Principal Investigator: Mark C Bates, MD West Virginia University
  More Information

No publications provided

Responsible Party: Vascular Dynamics, Inc. Identifier: NCT01831895     History of Changes
Other Study ID Numbers: CALM-FIM_US, CRD0152, G130013
Study First Received: April 9, 2013
Last Updated: May 26, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Vascular Dynamics, Inc.:
Carotid Sinus processed this record on October 09, 2015